Numerous randomized controlled trials (RCTs) have conclusively demonstrated that the combination of CDK4/6 inhibitors with ET effectively manages HR+/HER2-breast cancer, curtails the dissemination of cancer cells, and markedly improves patients' quality of life and survival rates [[5], [6], [7], [8]]. This evidence concerns the gene ERBB2 and breast carcinoma.